Cargando…

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Katsuhiro, Ishida, Mitsuaki, Yanai, Hirotsugu, Tsuta, Koji, Sekimoto, Mitsugu, Sugie, Tomoharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462691/
https://www.ncbi.nlm.nih.gov/pubmed/34559865
http://dx.doi.org/10.1371/journal.pone.0257860
_version_ 1784572248966823936
author Yoshikawa, Katsuhiro
Ishida, Mitsuaki
Yanai, Hirotsugu
Tsuta, Koji
Sekimoto, Mitsugu
Sugie, Tomoharu
author_facet Yoshikawa, Katsuhiro
Ishida, Mitsuaki
Yanai, Hirotsugu
Tsuta, Koji
Sekimoto, Mitsugu
Sugie, Tomoharu
author_sort Yoshikawa, Katsuhiro
collection PubMed
description BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy is a critical issue. Several assays have been used to evaluate PD-L1 expression, and a few studies comparing PD-L1 expression using various primary antibodies in TNBC tissues have been reported. However, the expression profiles of the PD-L1 using the 73–10 assay have not yet been analyzed in TNBC tissues. METHODS: We analyzed the PD-L1 immunohistochemical profiles of 62 women with TNBC using the 73–10, SP142 (companion diagnostic for atezolizumab), and E1L3N assays. PD-L1 expression on immune cells (ICs) and tumor cells (TCs) was also evaluated, and PD-L1 positivity was defined as a PD-L1-expressing ICs or TCs ≥ 1%. RESULTS: The expression rates of PD-L1 were 79.0%, 67.7%, and 46.8% on ICs, and 17.7%, 6.5%, and 12.9% on TCs using the 73–10, SP142, and E1L3N assays, respectively. The concordance rates between the 73–10 and SP142 assays were 85.5% (on ICs) and 88.7% (on TCs), respectively, and substantial agreement on ICs (coefficient 0.634) and moderate agreement (coefficient 0.485) on TCs were noted. Sample age and tumor diameter did not influence the ratio of PD-L1 expression among the assays. CONCLUSIONS: The positive rate on ICs and TCs of the 73–10 assay was higher than that of the SP 142 and E1L3N assays. Although substantial agreement on ICs and moderate agreement on TCs between the 73–10 and SP142 assays was noted in the present cohort, further studies are needed to clarify the PD-L1 expression status using various primary antibodies in a larger patient population. This would lead to the establishment of an effective evaluation method to assess the predictive value of anti-PD-L1 immunotherapy.
format Online
Article
Text
id pubmed-8462691
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84626912021-09-25 Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer Yoshikawa, Katsuhiro Ishida, Mitsuaki Yanai, Hirotsugu Tsuta, Koji Sekimoto, Mitsugu Sugie, Tomoharu PLoS One Research Article BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy is a critical issue. Several assays have been used to evaluate PD-L1 expression, and a few studies comparing PD-L1 expression using various primary antibodies in TNBC tissues have been reported. However, the expression profiles of the PD-L1 using the 73–10 assay have not yet been analyzed in TNBC tissues. METHODS: We analyzed the PD-L1 immunohistochemical profiles of 62 women with TNBC using the 73–10, SP142 (companion diagnostic for atezolizumab), and E1L3N assays. PD-L1 expression on immune cells (ICs) and tumor cells (TCs) was also evaluated, and PD-L1 positivity was defined as a PD-L1-expressing ICs or TCs ≥ 1%. RESULTS: The expression rates of PD-L1 were 79.0%, 67.7%, and 46.8% on ICs, and 17.7%, 6.5%, and 12.9% on TCs using the 73–10, SP142, and E1L3N assays, respectively. The concordance rates between the 73–10 and SP142 assays were 85.5% (on ICs) and 88.7% (on TCs), respectively, and substantial agreement on ICs (coefficient 0.634) and moderate agreement (coefficient 0.485) on TCs were noted. Sample age and tumor diameter did not influence the ratio of PD-L1 expression among the assays. CONCLUSIONS: The positive rate on ICs and TCs of the 73–10 assay was higher than that of the SP 142 and E1L3N assays. Although substantial agreement on ICs and moderate agreement on TCs between the 73–10 and SP142 assays was noted in the present cohort, further studies are needed to clarify the PD-L1 expression status using various primary antibodies in a larger patient population. This would lead to the establishment of an effective evaluation method to assess the predictive value of anti-PD-L1 immunotherapy. Public Library of Science 2021-09-24 /pmc/articles/PMC8462691/ /pubmed/34559865 http://dx.doi.org/10.1371/journal.pone.0257860 Text en © 2021 Yoshikawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yoshikawa, Katsuhiro
Ishida, Mitsuaki
Yanai, Hirotsugu
Tsuta, Koji
Sekimoto, Mitsugu
Sugie, Tomoharu
Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
title Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
title_full Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
title_fullStr Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
title_full_unstemmed Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
title_short Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
title_sort immunohistochemical comparison of three programmed death-ligand 1 (pd-l1) assays in triple-negative breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462691/
https://www.ncbi.nlm.nih.gov/pubmed/34559865
http://dx.doi.org/10.1371/journal.pone.0257860
work_keys_str_mv AT yoshikawakatsuhiro immunohistochemicalcomparisonofthreeprogrammeddeathligand1pdl1assaysintriplenegativebreastcancer
AT ishidamitsuaki immunohistochemicalcomparisonofthreeprogrammeddeathligand1pdl1assaysintriplenegativebreastcancer
AT yanaihirotsugu immunohistochemicalcomparisonofthreeprogrammeddeathligand1pdl1assaysintriplenegativebreastcancer
AT tsutakoji immunohistochemicalcomparisonofthreeprogrammeddeathligand1pdl1assaysintriplenegativebreastcancer
AT sekimotomitsugu immunohistochemicalcomparisonofthreeprogrammeddeathligand1pdl1assaysintriplenegativebreastcancer
AT sugietomoharu immunohistochemicalcomparisonofthreeprogrammeddeathligand1pdl1assaysintriplenegativebreastcancer